Use the hyperlinks, where available to access additional clinical trial information.
A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
This trial as one experimental arm. Participants will receive Atezolizumab 1200 mg Day 1 of each 21 day cycle intravenously, Bevacizumab 15 mg/kg Day 1 of each 21 day cycle intravenously, Gemcitabine 1000 mg/m2 Day 1 and 8 of each 21 day cycle intravenously, and Carboplatin AUC 5 Day 1 of each 21 day cycle intravenously.